Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

被引：0

作者：

Laura A. Huppert ^{[1
]}

Reshma Mahtani ^{[2
]}

Samantha Fisch ^{[1
]}

Naomi Dempsey ^{[2
]}

Sarah Premji ^{[3
]}

Angelina Raimonde ^{[4
]}

Saya Jacob ^{[1
]}

Laura Quintal ^{[1
]}

Michelle Melisko ^{[1
]}

Jo Chien ^{[1
]}

Ana Sandoval ^{[2
]}

Lauren Carcas ^{[2
]}

Manmeet Ahluwalia ^{[2
]}

Natasha Harpalani ^{[2
]}

Jenna Hoppenworth ^{[3
]}

Anne Blaes ^{[5
]}

Kelly Blum ^{[1
]}

Mi-Ok Kim ^{[1
]}

Dame Idossa ^{[5
]}

Ruta Rao ^{[4
]}

Karthik V. Giridhar ^{[3
]}

Hope S. Rugo ^{[1
]}

机构：

[1] University of California, San Francisco, San Francisco, CA

[2] Miami Cancer Institute, Baptist HealthSouth Florida, Miami, FL

[3] Mayo Clinic, Rochester, Rochester, MN

[4] Rush, Chicago, IL

[5] University of Minnesota, Minneapolis, MN

来源：

npj Breast Cancer | / 11卷 / 1期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/s41523-025-00748-5

中图分类号：

学科分类号：

摘要：

Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 patients with HER2-low MBC treated sequentially with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in either order at 5 institutions between 2020–2024. We evaluated clinical parameters associated with time to treatment failure (TTF) and real-world overall survival (rwOS). Median TTF was longer for ADC1 than ADC2, irrespective of HR-status, ADC sequence order, age ≤65 or >65 years, presence of visceral disease, or use of an intervening therapy. Younger age, longer time from MBC diagnosis to start of ADC1, and receipt of SG as ADC1 were associated with longer rwOS from start of ADC1. This cohort represents one of the first multicenter retrospective series of patients treated with sequential ADCs for HER2-low MBC, which may inform clinical practice. © The Author(s) 2025.

引用

共 15 条

[1] Bardia A., Et al., Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, N. Engl. J. Med, 384, pp. 1529-1541, (2021)
[2] Rugo H.S., Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Presented at: ESMO, (2022)
[3] Modi S., Et al., Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, N. Engl. J. Med, 387, pp. 9-20, (2022)
[4] Bardia A., Et al., Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01, J. Clin. Oncol, 43, pp. 285-296, (2025)
[5] Modi S., Et al., Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer, N. Engl. J. Med, 382, pp. 610-621, (2020)
[6] Andre F., Et al., Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial, Lancet, 401, pp. 1773-1785, (2023)
[7] Abelman R., Spring L., Fell G., Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study, Presented at: ASCO, (2023)
[8] N., Klar, M., Ferraro, E. & Bromberg, M. Real World OUrcomes of Sequential ADC Therapy in Metastatic Breast Cancer: Patients Treated with Sacituzumab govitecan and Trastuzumab deruxtecan. Presented at, (2024)
[9] Poumeaud F., Et al., Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer, Br. J. Cancer, 131, pp. 702-708, (2024)
[10] Presented at, (2024)

← 1 2 →